Key result
Lp-PLA2 may serve as a novel biomarker for diagnosing and evaluating cardiovascular disease severity in patients with type 2 diabetes mellitus.
Why the study?
Does Lp-PLA2 predict cardiovascular disease severity in patients with type 2 diabetes mellitus?
Does Lp-PLA2 predict cardiovascular disease severity in patients with type 2 diabetes mellitus?
Lp-PLA2 is highlighted as a potential novel biomarker for predicting and evaluating cardiovascular disease in patients with type 2 diabetes mellitus.
Requires prospective validation before any clinical use; leaves open Lp-PLA2's role as a T2DM biomarker.
Cardiovascular disease (CVD) is the fatal complication of diabetes mellitus and it is a large economic burden of the world. Although there are a few biomarkers in predicting the cardiovascular disease, the disease is still far from being diagnosed and evaluated precisely in type 2 diabetes mellitus (T2DM) patients. Lp-PLA2 takes part in several links of the pathological mechanism in the diabetic cardiovascular disease. Researches have implied that the Lp-PLA2 has positive association with CVD severity in T2DM. Lp-PLA2 may be a novel biomarker diagnosing and evaluating CVD in T2DM.
No takes yet. Share an insight, caveat, or question.
Huolan Amelia Zhu (2016) conducted a review in Cardiovascular disease in Type 2 Diabetes Mellitus. Lp-PLA2 was evaluated. Lp-PLA2 may serve as a novel biomarker for diagnosing and evaluating cardiovascular disease severity in patients with type 2 diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: